Agfa’s full year financial results for 2024 show a significant decline in demand for medical film which has all but wiped out what would otherwise have been a good result for its key Digital Print and Chemicals division with the group ending the year with revenues 1.1 percent down on the previous year at €1,138 million.
The Digital Print and Chemicals division saw revenues improve 7.2 percent, from €409 million in 2023 to €438 million in 2024. The Earnings Before Interest, Taxes, Depreciation and Amortisation, minus adjustments and restructuring costs, rose 65.2 percent, from €18.6 million or 4.6 percent of revenue, to €30.8 million, or 7 percent of revenue. This is mostly due to the continued growth in sales of the Zirfon membranes for renewable-powered green hydrogen production, which grew by 27 percent. In the fourth quarter, Stiesdal Hydrogen chose Agfa’s Zirfon membrane for use in its dynamic HydroGen alkaline water electrolyzers (AWE) for green hydrogen production.
However, Agfa cautions that Western markets for hydrogen production slowed down as legislation is still too complex or being clarified. Markets in the Middle East, Africa and Asia show more momentum and an increasing focus on high performing systems (using composite materials like Zirfon). Agfa has also picked up its first major customer in India.
Pascal Juéry, President and CEO of the Agfa-Gevaert Group, commented: “In just a few years, we have evolved our Green Hydrogen Solutions business from an R&D project into a thriving start-up, with continuous and robust sales growth. Our Zirfon membranes have set the industry standard and are utilized in the world’s largest hydrogen projects.”
He added: “Our Digital Printing Solutions division has reached a critical mass, fuelled by strategic decisions and successful product launches. In 2024, we achieved double-digit revenue growth and doubled the profit for this business.”
Digital Printing has grown gradually quarter-on-quarter to 13 percent for the full year. Agfa expects to build further momentum with its digital printing portfolio for the Sign & Display market segment in 2025, based on recent product launches and on the global strategic partnership between Agfa and EFI for digital printing equipment. Overall, Agfa successfully launched three new Sign & Display printers in 2024, shifting the portfolio to faster and higher end machines. Agfa is planning to launch at least four major products this year, suggesting the company will be busy at this year’s Fespa show in Berlin.
Furthermore, Agfa made good progress in the industrial and packaging segment of the market, installing its first SpeedSet Orca 1060 packaging printer at The Delta Group in the UK. The plan is that this will start to contribute to Agfa’s results in 2025. Recently, Agfa signed a multi-year contract with BHS Corrugated for the exclusive delivery of single pass water-based corrugate printers and ink supply. This builds on a project started by Inca Digital, with Agfa now taking over the ink supply. The first machines with the Agfa inks will be installed in 2025.
Indeed, Agfa continues to see year-on-year improvements to its ink revenues, up 15 percent for 2024, which once again is said to be mainly down to the ongoing program to convert former Inca customers to Agfa’s ink sets.
Over in the HealthCare IT division, revenues fell 3 percent, from €249 million in 2023 to €242 million in 2024, which Agfa puts down to the market transition to cloud technology. The division saw a record 32% increase in order intake starting from €124.6 million the year before to €164.8 million, mainly due to cloud-related contracts with high-profile new customers. Recurring revenue however, grew by 4% and now amounts to 57% of the total revenue for the year.
The HealthCare IT’s gross profit margin improved from 46.5 percent in 2023 to 48.8 percent, the highest percentage this division has achieved. The adjusted EBITDA margin evolved from 12.5 percent to 13.6 percent, with a stronger performance in the fourth quarter of the year. This is mainly due to the increased revenues from services and a higher mix of Agfa’s own IP software in the total sales,
Juéry explained: “Over the past three years, we have meticulously rebuilt the strategic foundations of our HealthCare IT division, transforming it into a strong player in the cloud segment of its market. This transformation has led to an unprecedented surge in order intake for the year.”
However, there is a much less rosy picture in the Radiology Solutions division, mainly due to the overall market for film declining as digital solutions become more popular. Thus revenues fell 9.8 percent from €425 million to €383 million in 2024. The adjusted EBITDA dropped 57.7 percent from €37.5 million to €15.9 million. Agfa has acknowledged that some of this is due to manufacturing inefficiencies and has a plan in place to address this, which should show some improvements in the second half of 2025. On the digital side, Agfa did see improvements to its Direct Radiography (DR) and Computed Radiography (CR).
Agfa reached an agreement with its social partners to stop the production and assembly of CR plates and cassettes at its Schrobenhausen site in Germany, resulting in the closure of this facility. Juery commented: “This self-funding program aims to reduce costs by €50 million by the end of 2027, with initial savings expected in the second half of 2025.”
Finally, Agfa continues to service its former Offset Solutions division, which was sold to Aurelius Group in April 2023. The revenues here have increased from €68 million to €75 million with the adjusted EBITDA rising from 3.9 percent of revenue to 7.6 percent.
Overall, there is much for Agfa to be pleased with in this figures. The company is in the midst of a multi-year transition that is now starting to pay off. There have been real improvements to the digital printing business, while the Zirfon membranes are starting to take off with further growth predicted as more manufacturing capacity comes on-stream.
Agfa is riding the transition within the Healthcare IT business, as this market embraces more cloud-based technology. There are continuing problems within the Radiology Solutions that is bringing the results for the whole group down, but Agfa appears to be working through this. Nonetheless, the bottom line is that the group made a net loss of €92 million, which is still an improvement on the 2023 loss of €101 million.
Juéry noted: “In 2024, we continued to capitalize on the successful strategies we designed for our growth engines. Our HealthCare IT, Digital Printing Solutions and Green Hydrogen Solutions divisions all achieved record-high EBITDA figures in the fourth quarter of 2024 and delivered excellent full year results.”
You can find further details on the Agfa-Gevaert Group from agfa.com.


Leave a Reply